Key result
Hepatic chemoembolization yields ~60% 1-year survival in patients with hepatocellular carcinoma.
Why the study?
Does hepatic chemoembolization with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol improve response and survival in a U.S. population with hepatocellular carcinoma?
Population
38 consecutive patients with hepatocellular carcinoma in a U.S. population.
Design
Cohort
Follow-up
Up to 3 years
Authors
Loading...
Supports chemoembolization feasibility in U.S. HCC; extends international data but leaves open need for randomized confirmation.
Cohort (n=38)
Does hepatic chemoembolization with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol improve response and survival in a U.S. population with hepatocellular carcinoma?
Hepatic chemoembolization for advanced hepatocellular carcinoma in a U.S. population yields response and survival rates comparable to those reported in Asia and Europe.
Solomon et al. (1999) conducted a cohort in Hepatocellular carcinoma (n=38). Hepatic chemoembolization with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol was evaluated on Response and survival. Hepatic chemoembolization in patients with hepatocellular carcinoma yielded cumulative survival rates of 60% at 1 year, 41% at 2 years, and 16% at 3 years, with a 30-day mortality of 3%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: